Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)
Event:
ESC Congress 2023
Topic:
Hypertrophic Cardiomyopathy
Session:
Contemporary management of hypertrophic cardiomyopathy
